Description
In episode 1 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss what practicing clinicians need to know about newly approved oral JAK inhibitors. This activity focuses on the mechanism of action of novel targeted agents, their key safety and efficacy data, and their role in the treatment paradigm for atopic dermatitis.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated.
Speakers
Sakina S. Bajowala, MD, FAAAAI
Board-Certified Allergist & Immunologist
Kaneland Allergy & Asthma Center
North Aurora, IL
Dr. Sakina Shikari Bajowala is an internationally recognized physician, best-selling author, speaker, and health advocate.
The Medical Director of Kaneland Allergy and Asthma Center, Dr. Bajowala is an expert in the highly specialized field of food allergen desensitization. She has successfully treated hundreds of patients with life-threatening food allergies, and has developed her own integrative protocols to optimize the safety and efficacy of this immunomodulatory procedure. Dr. Bajowala is also the author of the #1 best-selling book, "The Food Allergy Fix: An Integrative and Evidence-Based Approach to Food Allergen Desensitization", and is a dynamic educator and speaker on the topic of integrative food allergy treatments.
Dr. Bajowala dedicates her volunteer time to a variety of advocacy efforts, including food allergy, physician wellness, consumer safety, and environmental health.
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
Dr. Neal Bhatia is a board-certified dermatologist in San Diego, California. He serves as Director of Clinical Dermatology at Therapeutics Clinical Research. He is a chief medical editor for Practical Dermatology. He has a background in immunology and has interests in mechanisms of therapy, skin cancer, and medical dermatology.
In 2022, Dr. Bhatia is the Secretary/Treasurer of the Noah Worcester Dermatological Society, and just completed his term as the Vice President of the American Academy of Dermatology.
Temitayo A. Ogunleye, MD
Associate Professor and Associate Director of
Diversity, Equity and Inclusion
University of Pennsylvania Department of Dermatology
Philadelphia, PA
Dr. Temitayo A. Ogunleye, is an Associate Professor and Associate Director of Diversity, Equity and Inclusion of the University of Pennsylvania Department of Dermatology. She received her medical degree from the University of Pennsylvania Perelman School of Medicine, completed her residency training at the University of Michigan, and trained at the University of Pennsylvania as a Clinician Educator Fellow. Her areas of interest include skin of color, hair disorders, and increasing diversity in medicine.
Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Dr. Jonathan I. Silverberg is a Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg’s area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. He has extensive experience in the advanced management of atopic dermatitis, contact dermatitis, hand eczema, chronic itch, psoriasis, hidradenitis and many other chronic inflammatory skin disorders. He is also a national expert in allergy patch testing, phototesting and photopatch testing.
Dr. Silverberg’s research interests include the epidemiology of chronic and infectious diseases. He has published extensively on the epidemiology of chronic inflammatory skin diseases such as eczema, psoriasis and autoimmune blistering disorders as well infections such as COVID-19, measles, shingles, cellulitis and other skin and serious infections. Dr. Silverberg has also made major contributions to health services research, patient-reported outcome development, understanding comorbidities and burden of itch and inflammatory skin disease, advancing evidence-based dermatology, drug development, and clinical trial design. His publications include more than 1000 peer-reviewed articles, abstracts and book chapters. He is also the author of the Clinical Management of Atopic Dermatitis handbook (second edition published 2022).
Accreditation and Disclosure Information
Target Audience
This CE activity is intended for dermatologists and allergists who are involved in the care and treatment of patients with atopic dermatitis.
Educational Objectives
After completing this CE activity, the participant should be better able to:
-
Evaluate emerging safety and efficacy data for new and novel targeted therapies for AD
-
Plan strategies to enhance care of individuals with AD, including patients of diverse backgrounds
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Support Statement
This CE activity is supported by an educational grant from Pfizer.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
Neal Bhatia, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AbbVie, Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals, Inc., Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, EPI Health, Ferndale Pharma Group, Foamix Pharmaceuticals Ltd., Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Pharmaceuticals Corp, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, Sanofi, Stemline Therapeutics, Sun Pharma, and VYNE Therapeutics Inc.
Advisory Board/Consultant for AbbVie, Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals, Inc., Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, EPI Health, Ferndale Pharma Group, Foamix Pharmaceuticals Ltd., Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Pharmaceuticals Corp, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, Sanofi, Stemline Therapeutics, Sun Pharma, and VYNE Therapeutics Inc.
Speakers’ Bureau with AbbVie, Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals, Inc., Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, EPI Health, Ferndale Pharma Group, Foamix Pharmaceuticals Ltd., Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Pharmaceuticals Corp, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, Sanofi, Stemline Therapeutics, Sun Pharma, and VYNE Therapeutics Inc.
Research Grant from Arcutis Biotherapeutics, Biofrontera Inc., Bristol Myers Squibb, Boehringer Ingelheim, Dermavant Sciences, Galderma, LEO Pharma, Lilly, and Ortho Pharmaceuticals Corp.
Planner/Presenter
Sakina S. Bajowala, MD, FAAAAI
Board-Certified Allergist & Immunologist
Kaneland Allergy & Asthma Center
North Aurora, IL
Sakina S. Bajowala, MD, FAAAAI, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Solid Starts LLC.
Advisory Board/Consultant for Solid Starts LLC.
Independent Contractor for Novartis Pharmaceuticals Corporation.
Other with Wise Prince, LLC – owner (healthcare software).
Planner/Presenter
Temitayo A. Ogunleye, MD
Associate Professor and Associate Director of Diversity, Equity and Inclusion
University of Pennsylvania Department of Dermatology
Philadelphia, PA
Temitayo A. Ogunleye, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for Janssen Pharmaceuticals.
Advisory Board/Consultant for Janssen Pharmaceuticals.
Presenter
Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Jonathan I. Silverberg, MD, PhD, MPH, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant for AbbVie, AFYX Therapeutics, AOBiome, Arena Pharmaceuticals, Inc., Asana BioSciences, ASLAN Pharmaceuticals, BiomX, Biosion, Blue Fin Group, Bodewell, Boehringer Ingelheim, Cara Therapeutics Inc, Celgene Corporation, Connect Biopharma, Dermavant Sciences, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Luna Pharmaceuticals, Inc., Menlo Therapeutics, Novartis Pharmaceuticals Corporation, Optum, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi Genzyme, Shaperon, and Sidekick Health.
Speakers’ Bureau with AbbVie, Eli Lilly, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme.
Research Grant from AbbVie, Eli Lilly, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc | All Rights Reserved